National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04145141|
Recruitment Status : Not yet recruiting
First Posted : October 30, 2019
Last Update Posted : March 8, 2021
Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments.
To better understand liver cancer.
People ages 18 and older who have liver cancer and had or are planning to have immune therapy
Participants will be screened with a review of their medical records. They will be asked about their medical history and test results.
Participants will come to the NIH Clinical Center. During this visit, their medical records, test results, imaging studies, and tissue samples (if available) will be gathered. Participants will learn the results of a test to see if they have any mutations known to be connected to cancer. They will learn if there are treatment options for them. Participants will give blood, urine, and stool samples or rectal swabs.
Participants will not have follow-up visits just for this study. If they join another NIH research study and have visits for this other study, their medical records; test results; and blood, urine, and stool samples may be collected. This will occur about every 3 months. If they have a biopsy or surgery on another study or as part of treatment and there is leftover tissue, researchers would like to collect some of that tissue.
Participants will be contacted every 6 months by phone or e-mail. They will be asked about their health. They will provide any medical records, test results, and imaging studies.
Participants will be followed on this study for life.
|Condition or disease|
|Hepatocellular Carcinoma Liver Cancer Cholangiocarcinoma|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)|
|Estimated Study Start Date :||March 11, 2021|
|Estimated Primary Completion Date :||December 31, 2025|
|Estimated Study Completion Date :||December 31, 2025|
1/ Cohort 1
Subjects with a diagnosis or suspicion of PLC
- To establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of PLC development and progression [ Time Frame: 5 years ]Established biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of PLC development and progression
- To estimate 3 years progression-free survival following immunotherapy for PLC [ Time Frame: 3 years ]Proportion of patients that have progressive disease after 3 years.
- To estimate overall survival following immunotherapy for PLC [ Time Frame: death ]Median amount of time subject survives from the beginning of immunotherapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04145141
|Contact: Anuradha Budhu, M.D.||(240) email@example.com|
|United States, California|
|USC Norris Comprehensive Cancer Center, Keck School of Medicine|
|Los Angeles, California, United States, 90033|
|Contact: Anthony El-Khoueiry, M.D. Not Listed firstname.lastname@example.org|
|David Geffen School of Medicine|
|Los Angeles, California, United States, 90095|
|Contact: Richard Finn 310-829-5471 RFinn@mednet.ucla.edu|
|USCF Hellen Diller Family Comprehensive Cancer Center|
|San Francisco, California, United States, 94158|
|Contact: Robin K Kelley 415-353-7065 Katie.Kelley@ucsf.edu|
|United States, District of Columbia|
|Washington, District of Columbia, United States, 20007-2197|
|Contact: Ruth He 202-444-2223 email@example.com|
|United States, Maryland|
|Johns Hopkins University|
|Baltimore, Maryland, United States, 21205|
|Contact: Mark Yarchoan, MD 214-648-6137 firstname.lastname@example.org|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|United States, Massachusetts|
|Massachusetts General Hospital Cancer Center|
|Boston, Massachusetts, United States, 02114|
|Contact: Andrew Zhu 617-724-4000 email@example.com|
|United States, New York|
|Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College|
|New York, New York, United States, 10021|
|Contact: Ghassan Abou-Alfa 646-888-4184 abou-alg@MSKCC.ORG|
|United States, Pennsylvania|
|Thomas Jefferson University|
|Philadelphia, Pennsylvania, United States, 19107-6541|
|Contact: Hien Dang, PhD 215-955-1621 Hien.Dang@jefferson.edu|
|United States, Texas|
|University of Texas at Southwestern|
|Dallas, Texas, United States, 75390|
|Contact: Yujin Hoshida, MD 214-648-6137 Yujin.Hoshida@UTSouthwestern.edu|
|The University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Contact: Ahmed Kaseb 713-792-2828 firstname.lastname@example.org|
|Principal Investigator:||Tim F Greten, M.D.||National Cancer Institute (NCI)|